Log In
Print
BCIQ
Print
Print this Print this
 

Replagal, agalsidase alfa

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionInjectable alpha galactosidase A enzyme
Molecular Target Not available
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationFabry's disease
Indication DetailsTreat Fabry's disease
Regulatory Designation

U.S. - Fast Track (Treat Fabry's disease);
U.S. - Priority Review (Treat Fabry's disease)

Partner

Endo International plc; Sumitomo Dainippon Pharma Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today